However, future studies on melanoma specimens resistant to targeted therapies are needed to address the relevance of the phenotype in determining the next therapeutic strategy for melanomas resistant to BRAFV600/MEK inhibitors. This evidence concerns the gene MAP2K7 and melanoma.